导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -14.58% | 4014/4700 |
| 近一周 | -2.17% | 3442/5371 |
| 近一月 | 0.20% | 647/5328 |
| 近一季 | -8.02% | 3017/5140 |
| 近半年 | -17.28% | 4163/4839 |
| 近一年 | -1.84% | 2955/4338 |
| 近两年 | 41.72% | 1802/2925 |
| 近三年 | 12.43% | 1674/2229 |
| 成立以来 | 89.66% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.37% 3607/4961 |
-1.96% 3379/5312 |
- - |
- - |
| 2025 | 29.65% 1386/4813 |
-1.68% 2740/3635 |
11.18% 208/4076 |
7.15% 3472/4524 |
10.69% 181/4813 |
| 2024 | 8.17% 1581/3463 |
-5.83% 1955/2808 |
-2.22% 1154/3014 |
12.40% 2357/3129 |
4.52% 701/3463 |
| 2023 | -10.39% 1301/2656 |
1.20% 1617/2280 |
2.91% 117/2385 |
-10.29% 1980/2515 |
-4.08% 865/2655 |
| 2022 | -25.45% 1318/2207 |
-21.75% 1650/1919 |
3.66% 1114/2016 |
-7.52% 132/2113 |
-0.62% 1629/2208 |
| 2021 | 13.29% 359/1822 |
-17.42% 1199/1255 |
9.89% 515/1330 |
6.96% 203/1466 |
16.73% 50/1822 |
| 2020 | 63.09% 112/1250 |
-1.27% 212/1028 |
10.87% 754/1067 |
27.19% 24/1164 |
17.14% 136/1184 |
| 2019 | 23.16% 633/1092 |
29.94% 266/739 |
-8.97% 624/788 |
5.09% 167/850 |
-0.92% 893/918 |
| 2018 | - - |
- - |
-16.82% 566/631 |
2.81% 97/660 |
-12.43% 445/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证军工ETF联接C VS. 长安沪深300非周期A(740101) |